Skip to main content

Table 3 Reporting method of FEV 1 for all included trials for each scale (liter or % of predicted) and statistical method of reporting, at baseline (T 0 ) and endpoint (T e )

From: A systematic review with attempted network meta-analysis of asthma therapy recommended for five to eighteen year olds in GINA steps three and four

Scale of FEV1

Outcome summary measure

Reference number of study reporting summary measure at T0 a

Reference number of study reporting summary measure at Te b

Liter

Mean

 

13, 15, 19

 

Mean change

 

10, 14, 18

 

Mean + SE or SD

8, 10, 11, 16, 18, 22, 23

8, 16

 

Mean change + SE or SD

 

23

 

Mean + range

14, 15, 16, 19

16

 

P-value versus another arm

 

10, 14, 15, 18, 19, 23

 

Difference between arms + 95%CI

 

13, 23

% of predicted

Mean

 

13

 

Mean change

 

11, 12, 18

 

Mean + SE or SD

2, 3, 5, 6, 7, 9, 10, 11, 16, 17, 18, 20, 21, 22

2, 3, 6, 7, 9, 16, 17, 20

 

Mean change + SE or SD

  
 

Mean + range

12, 13, 14, 15, 16, 17, 19

16

 

P-value versus another arm

 

11, 12, 18

 

Difference between arms + 95%CI

 

13, 17

  1. aT0 = baseline of the trial.
  2. bTe = endpoint of the trial, varying from 4 to 56 weeks.
  3. Reporting method of all included trials for each scale (litre or % of predicted) and statistical method of reporting, at baseline (T0) and endpoint (Te).